Initiate a first-in-human study for Amilo-5MER
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- March 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plan to initiate a first in human study by the first quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company initiated the first-in-human Phase 1 trial of Amilo-5MER in March 2021, meeting the commitment to start the study by the end of the first quarter of 2021.
-
A Galmed Pharmaceuticals Ltd. 20-F filed 2022-05-02
“In March 2021, we dosed the first subject in our first in human Phase 1 trial of Amilo-5MER for the treatment of chronic inflammatory diseases.” ✓ confirmed on the page
Market reaction: the shares moved -50.8% against the S&P 500 over the three sessions around the disclosure (29 Apr 2022 to 4 May 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- first-in-human study for Amilo-5MER
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Galmed Pharmaceuticals Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-EOCN-022399 · Corrections policy